资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.

J Hematol Oncol. 2019-03;

LvJiang, ZhaoRuocong, WuDi, ZhengDiwei, WuZhiping, ShiJingxuan, WeiXinru, WuQiting, LongYouguo, LinSimiao, WangSuna, WangZhi, LiYang, ChenYantao, HeQing, ChenSuimin, YaoHuihui, LiuZixia, TangZhaoyang, YaoYao, PeiDuanqing, LiuPentao, ZhangXuchao, ZhangZhenfeng, CuiShuzhong, ChenRen, Li

Products/Services Used	Details	Operation
Catalog Antibody	Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen receptor (CAR) T cells. Mesothelin targeting CAR-T has been reported …containing the DAP10 cytoplasmic sequence were synthesized by Genscript (Nanjing) Co	Get A Quote

摘要

Gastric cancer (GC) is a common cancer in Asia and currently lacks a targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed in GC tissue and could be targeted by chimeric antigen receptor (CAR) T cells. Mesothelin targeting CAR-T has been reported in mesothelioma， lung cancer， breast cancer， and pancreas cancer. However， the feasibility of using anti-MSLN CAR T cells to treat GC remains to be studied.